Oncaidia's best practice
Wednesday, 30 July, 2008
Adelaide biotech Oncaidia [ASX: ONA] has been awarded an Asia-Pacific Frost & Sullivan Technology Innovation Award for its Apomab monoclonal antibody technology.
The award celebrates innovative work in the field of cancer diagnosis and therapy.
Oncadia was awarded it for the company's proprietary Apomab technology, which is used for detection, treatment and assessment of a range of cancers including lung, breast and prostate.
Apomab is able to identify the presence of the La protein, an autoantigen that is also overexpressed in cancer cells.
The technology promises to target cancers more accurately, reducing side effects and providing more effective treatment.
Clinical trials of Apomab are set to commence shortly.
Frost & Sullivan conduct Best Practices Awards annually. The winners are determined by industry analysts in a thorough comparison process.
Researchers genetically engineer snake antivenom
An international team of researchers has used genetic engineering to create so-called...
Common medications linked to adverse breast cancer outcomes
An international study has found concerning evidence about the impact of a range of common...
Saliva-based biosensor could improve heart failure detection
Scientists have created a biosensor that can rapidly detect the heart failure biomarker S100A7 in...
